about
Circulating microRNAs are new and sensitive biomarkers of myocardial infarctionThe role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinionPrevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trialCirculating levels of dimethylarginines, chronic kidney disease and long-term clinical outcome in non-ST-elevation myocardial infarction.Sustained benefit from ultrafiltration in moderate congestive heart failure.N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angina.Vitamin D plasma levels and in-hospital and 1-year outcomes in acute coronary syndromes: a prospective studyAcute Kidney Injury Definition and In-Hospital Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction.Extracorporeal fluid removal in heart failure patients.Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review.Extracorporeal ultrafiltration for heart failure: focus on organ cross talk and clinical trials.Ultrafiltration for congestive heart failure: the past and the present.Continuous ultrafiltration in acute decompensated heart failure: current issues and future directions.How to balance risks and benefits in the management of CKD patients with coronary artery disease.Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial.Acute kidney injury in patients with acute coronary syndromes.Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research.B-type natriuretic peptide levels in patients with pericardial effusion undergoing pericardiocentesis.Brain natriuretic peptide in acute myocardial infarction: a marker of cardio-renal interaction.Myocardial Infarct Size in Patients on Long-Term Statin Therapy Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.Questing for circadian dependence in ST-segment-elevation acute myocardial infarction: a multicentric and multiethnic study.High-sensitivity C-reactive protein is within normal levels at the very onset of first ST-segment elevation acute myocardial infarction in 41% of cases: a multiethnic case-control study.Diagnostic and Prognostic Utility of Circulating Cytochrome c in Acute Myocardial Infarction.A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes.Post-procedural hemodiafiltration in acute coronary syndrome patients with associated renal and cardiac dysfunction undergoing urgent and emergency coronary angiography.Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction.Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary intervention.Proteome of platelets in patients with coronary artery disease.High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy.Circadian distribution of acute myocardial infarction by anatomic location and coronary artery involvement.Circulating CD4+CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis.B-type natriuretic peptide and risk of acute kidney injury in patients hospitalized with acute coronary syndromes*.Serum to urinary sodium concentration ratio is an estimate of plasma renin activity in congestive heart failure.Continuous veno-venous hemofiltration for the treatment of contrast-induced acute renal failure after percutaneous coronary interventions.Continuous ultrafiltration for congestive heart failure: the CUORE trial.[The PRATO-ACS study].Use of levosimendan for treatment of cardiogenic shock associated with electrical storm.Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality.Can contrast-induced nephropathy after percutaneous coronary intervention be accurately predicted with a risk score?
P50
Q24606701-D1C3D076-1E9B-47C1-A818-13B7574151B5Q26745542-1C122070-A021-47FC-AC51-B27771FF3941Q28257023-A9BF01CA-6E89-4631-94B9-DFB7CFAF8663Q34489684-7E1CCB44-625F-4588-B6C9-B2DEB4EFAA7DQ34502959-E858B1FC-0E38-409B-A4F2-080403D26B0AQ34542789-4DE98691-8AE1-4610-BD89-657689E6BC78Q35048954-9BE3586B-D5E3-474C-94FE-3F640A2B42E1Q36151577-F0295A1F-7B6A-4D32-9922-4FA71B0EF0ABQ37240720-873FBB8E-B91A-4B46-99A4-DAE9B957B583Q37739156-53C8025A-0EAD-4A04-9E25-C638D912512EQ37971049-813AF153-7F7F-48D3-B34F-715BC8DFF406Q38226501-2329CBF8-66D9-406B-9A4E-013551A32E10Q38312848-EEF59399-3A1C-40EE-8CCE-25846F2DB6ACQ38343671-43C2FE20-E0A3-45A8-A390-3A5982EB9126Q38364890-387B1F4B-8F4C-4BD5-B112-6E8E83630973Q38477138-F6072BCA-B1AE-46D5-BD8E-DDEA1844C58FQ38561071-C1E96ADA-5FC0-4C76-B94B-3B6EB6E992D3Q38791497-65EE3BB6-6333-4B40-9FAC-CEA681CFA043Q38884063-D8EDCD96-649F-4A1C-9273-384735C5B4E4Q38918910-A9852116-6847-4318-8464-5C07DFD2E18EQ38939236-66D28388-23A8-4785-B96C-6FC1F6114B14Q39421459-D9AA6439-6B27-4B14-B243-70220FB583CFQ40011125-E681F43D-14A4-455A-9508-3A06C59744ACQ40501284-A75675D4-813D-4A17-BAEC-A21DC4217B20Q41464083-F7B8F8EB-6B4D-4157-A621-1F854A11A5F6Q41959172-4E44CD2B-C831-4F90-9549-77CE821BB44AQ42170160-18A48E50-FA03-40C2-85EC-AED6DF338E08Q42781472-61C5D312-3F9F-4227-9784-FB93BAAE237EQ43130993-8D71687F-D666-4169-A687-9A87CD74B31AQ43287852-DB8B7FE9-42FC-4569-AE4F-903DAA0776D2Q43493074-2E7EE024-CF3E-48FD-B1F7-C1137385ABADQ43507476-D533BBD7-0709-453B-9329-348D4CEC5DEFQ43610719-E540CDF9-9177-494D-9BC2-7970F024DFB0Q44202912-9316BDFF-7655-4B31-BA33-1A4F711C8FEDQ44267037-90BE31E1-91FB-43C2-88DD-CC0C4E24DD3CQ44870202-075F5FA2-6931-46EF-8199-EF4466EA21CCQ44957394-B9812BF6-0F0D-433C-BF45-C512E1FF27AEQ46006704-F4E49570-E661-46B7-AF25-B0DB08308ACBQ46135266-DE1ECF6E-E11C-42CE-83EC-C4DA089734F9Q46787225-7C21D5F1-AF2C-4B07-8D25-07FC5247E7E9
P50
description
researcher
@en
wetenschapper
@nl
name
G Marenzi
@en
G Marenzi
@nl
type
label
G Marenzi
@en
G Marenzi
@nl
prefLabel
G Marenzi
@en
G Marenzi
@nl
P106
P31
P496
0000-0003-4410-4461